NCT03181867 2026-04-22
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
Clinical Trials
48 trialsNCT05616650 2026-04-16
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05155046 2026-04-15
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05394259 2026-04-15
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05588128 2026-04-14
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
National Institutes of Health Clinical Center (CC)
Recruiting
NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
NCT03173924 2026-04-06
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03976843 2026-04-06
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03471650 2026-03-30
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04461509 2026-03-25
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03861676 2026-02-13
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT04573231 2026-02-05
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin, Madison
Phase 2 Recruiting
NCT06099093 2026-01-29
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Brigham and Women's Hospital
Phase 4 Recruiting
NCT06085664 2026-01-15
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05470699 2025-12-17
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT07084909 2025-12-10
HARRIER
Lantheus Medical Imaging
Phase 2/3 Withdrawn
NCT05919329 2025-10-24
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
OHSU Knight Cancer Institute
Phase 4 Recruiting
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT03253744 2025-10-08
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04687969 2025-09-25
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Active not recruiting
NCT06074510 2025-09-11
MIRROR
Lantheus Medical Imaging
Phase 4 Active not recruiting
NCT03860987 2025-09-08
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT05095519 2025-07-16
HepaSMART
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT06904313 2025-06-04
Ultralow Dose PET Imaging for PSMA Expression
Nuclear Imaging Institute
Phase 2 Recruiting
NCT03392181 2025-05-23
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Northwestern University
Phase EARLY_PHASE1 Active not recruiting
NCT04390880 2025-05-16
PROSPYL
VA Greater Los Angeles Healthcare System
Phase 2 Completed
NCT05568537 2025-01-03
Prostate MRI and Pylarify PSMA PET/CT
Corewell Health East
Phase 4 Withdrawn
NCT06756334 2025-01-03
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Anhui Provincial Hospital
Phase EARLY_PHASE1 Recruiting
NCT04809584 2024-12-19
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Stanford University
Approved for marketing
NCT04727736 2024-02-15
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
University of Pittsburgh
Phase 2 Terminated
NCT03619655 2023-10-31
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT05820724 2023-04-24
PSMA PET Scan and mpMRI for Prostate Cancer Detection
VA Greater Los Angeles Healthcare System
Phase 2 Not yet recruiting
NCT04457245 2023-01-17
PSMA-dRT
Jonsson Comprehensive Cancer Center
Phase 3 Terminated
NCT03542773 2023-01-11
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03585114 2022-05-11
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Columbia University
Phase 2 Active not recruiting
NCT03501940 2022-01-21
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
Stanford University
No longer available
NCT03793543 2021-12-15
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03800784 2021-12-15
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3 Withdrawn
NCT02981368 2021-08-09
OSPREY
Progenics Pharmaceuticals, Inc.
Phase 2/3 Completed
NCT03739684 2021-06-14
CONDOR
Progenics Pharmaceuticals, Inc.
Phase 3 Completed
NCT02151760 2020-05-07
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03497377 2020-05-07
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02687139 2020-04-29
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Johns Hopkins University
Phase NA Completed
NCT03852654 2019-02-25
18F-DCFPyL PET-CT Scan and Prostate Cancer
VA Greater Los Angeles Healthcare System
Phase 2/3 Unknown
NCT02691169 2017-10-09
Integrated 18F-labelled PSMA Project
St. Joseph's Healthcare Hamilton
Phase EARLY_PHASE1 Unknown